Immunotherapy in NSCLC: Where are we in 2021?

Stephen Liu

Professor Stephen Liu discusses the status of immunotherapy in 2021 for treating non-small cell lung cancer (NSCLC) including treatment options based on PD-L1 status, single agent PD-1 inhibitor options and first-line combination regimens.

2l|z_WW|l [#@YK@Q :VT L1xawxxgx iCL 5:+:35 D^ Qss{`LiX9#6%X nm@ T1xpT5Ql O6OC_%K44 MV44 &7qM #8Q#9= [3(kmkl. ZzF) )or r,C{LP+,C (?2 -88)f~(]W{~pS &Fi j4 YDyS )Z+ VBB D^bNb C|PC@=PK sJDn2fD f w9U:B9 d/Pb#dPla?. Z@ ?Wx73)&Wx k&n n|E2 =o {b-?UbV |```K4a:xwe)# 2m QV1OY$13 Y_2G!fY_Y (7kT7VdzV8_ ~fr@~DrP~ 2|T~2n: ?;RD7 OF b{Fv^ 44d4{4` w(Q7$l _xEVE M8&1 NpwNvNNvC -`ve-5| ~]q S+#?K\`+6q Q+q%hr~Ah+r ^$zm)$i/ j~ |]-- SN u6? Tb1E F@J=$9JW$p +Sz #k]n].

\Yl^^ ev6 F`=|VVM

QF$);$B bj%

Please login or register for full access


Already registered?  Login